The behavioral actions of lithium in rodent models: Leads to develop novel therapeutics
For nearly as long as lithium has been in clinical use for the treatment of bipolar disorder, depression, and other conditions, investigators have attempted to characterize its effects on behaviors in rodents. Lithium consistently decreases exploratory activity, rearing, aggression, and amphetamine-...
Saved in:
Published in | Neuroscience and biobehavioral reviews Vol. 31; no. 6; pp. 932 - 962 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Ltd
2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | For nearly as long as lithium has been in clinical use for the treatment of bipolar disorder, depression, and other conditions, investigators have attempted to characterize its effects on behaviors in rodents. Lithium consistently decreases exploratory activity, rearing, aggression, and amphetamine-induced hyperlocomotion; and it increases the sensitivity to pilocarpine-induced seizures, decreases immobility time in the forced swim test, and attenuates reserpine-induced hypolocomotion. Lithium also predictably induces conditioned taste aversion and alterations in circadian rhythms. The modulation of stereotypy, sensitization, and reward behavior are less consistent actions of the drug. These behavioral models may be relevant to human symptoms and to clinical endophenotypes. It is likely that the actions of lithium in a subset of these animal models are related to the therapeutic efficacy, as well the side effects, of the drug. We conclude with a brief discussion of various molecular mechanisms by which these lithium-sensitive behaviors may be mediated, and comment on the ways in which rat and mouse models can be used more effectively in the future to address persistent questions about the therapeutically relevant molecular actions of lithium. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-Review-3 content type line 23 ObjectType-Feature-3 ObjectType-Review-1 To whom correspondence should be addressed Bldg 35, Rm 1C-912 35 Convent Drive Bethesda, MD 20892-3711 gouldt@mail.nih.gov |
ISSN: | 0149-7634 1873-7528 |
DOI: | 10.1016/j.neubiorev.2007.04.002 |